Relationships among extrapyramidal symptoms, antipsychotic drug doses and neuroreceptor occupancy

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 2, 1998, Pages

  Nyberg, Svante ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 HT2 receptor occupancy; Antipsychotic drugs; D2 receptor occupancy; Extrapyramidal symptoms; Positron emission tomography; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SERTINDOLE;

DIAGNOSTIC APPROACH ROUTE; DOSE RESPONSE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW;

EID: 0032409271     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Ayd FJ, Jr (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175: 1054-60.
2. Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance. Schizophr Bull 23: 567-82.
3. Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19: 287-302.
4. Gilbert PL, Harris J, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52: 173-88.
5. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
6. Van Putten T, May PRA, Marder SR, Wittman LA (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-90.
7. McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739-45.
8. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-96.
9. Meltzer HY, Matsubara S, Lee J-C (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390-2.
10. Gerlach J (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 17: 289-309.
11. Nyberg S, Nilsson U, Okubo Y et al (1998) Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13 (suppl 3): S15-S20.
12. 2 dopamine receptor binding in the living human brain by PET. Science 231, 258-61.
13. Sedvall G, Farde L (1995) Chemical brain anatomy in schizophrenia. Lancet 346, 743-9.
14. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9: 696-708.
15. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Hum Psychopharmacol 7: 157-65.
16. 11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res 67: 163-71.
17. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110: 265-72.
18. 1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology 119: 1-8.
19. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-44.
20. 2 dopamine receptor occupancy and antipsychotic drug plasma levels in man. Int Clin Psychopharmacol 10 (suppl 3): 81-5.
21. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152: 173-8.
22. 2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Arch Gen Psychiatry 54: 953-8.
23. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79-91.
24. Volavka J, Cooper TB, Meisner M et al (1990) Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: A progress report. Psychopharmacol Bull 26: 13-17.
25. Volavka J, Cooper TB, Czobor P, Meisner M (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder [see comments]. Arch Gen Psychiatry 52: 837-45.
26. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and-haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154: 782-91.
27. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-9.
28. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263-87.
29. Nordström A-L, Farde L, Halldin C (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110: 365-7.
30. Casey DE (1989) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25: 457-9.
31. Marder SR, Meilbach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-35.
32. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-26.
33. Beasley CM, Jr., Tollefson G, Tran P et al (1996) Olanzapine versus placebo and haloperidol - acute phase results of the north American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-23.
34. Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders - results of an international collaborative trial. Am J Psychiatry 154: 457-65.
35. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-35.
36. 2 antagonistic properties. J Pharmacol Exp Ther 244: 685-93.
37. Leysen JE, Gommeren W, Eens A et al (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661-70.
38. Schotte A, Janssen PMF, Gommeren W et al (1996) Risperidone compared with new and reference antipsychotic drugs - in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
39. 2 receptor binding in risperidone-treated patients. J Clin Psychopharmacol 15 (suppl 1): 19S-23S.
40. 2 receptor occupancy induced by risperidone in schizophrenic patients. ACNP annual conference, San Juan, Puerto Rico, 9-13 December 1996.
41. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262: 545-51.
42. Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
43. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 124: 148-53.
44. 2 receptor occupancy in olanzapine treated patients. Arch Gen Psychiatry 55: 238-84.
45. Sánchez C, Arnt J, Dragsted N et al (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22: 239-50.
46. 2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J Neural Transmission-General Section 89: 61-9.
47. Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10: 25-33.
48. Tamminga CA, Mack RJ, Granneman GR et al (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12: S29-35.
49. Farde L, Mack RJ, Nyberg S, Halldin C (1997) D-2 occupancy, extrapyramidal side effects and antipsychotic drug treatment - a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 12: S3-7.
50. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacol 130: 152-8.
51. 123I-IBZM SPECT study. Psychopharmacology 136: 367-73.